Regularly updated material, in addition to our annual outputs. Includes specific information on adalimumab, natalizumab and ranibizumab biosimilars.

Understand the area

Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better value for certain conditions

Resources to support the choice of adalimumab biosimilar within organisations.

Understand the adalimumab products that are available on contract to the NHS. Choose between them appropriately for organisations or individuals.
Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.
Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.
One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.

Resources to specifically support the introduction of ranibizumab biosimilar for ocular use.

Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
Governance should consider processes for approval; procurement and supply; prescribing and administration; monitoring; and pharmacovigilance
Three licensed ranibizumab biosimilars are available: Byooviz, Ongavia and Ximluci. Learn about the licensed indications and supporting evidence